By otakuyassine3@gmail.com 
A number of firms have modified their ratings and price targets on shares of Sangamo Therapeutics (NASDAQ: SGMO) recently:
- 12/16/2024 – Sangamo Therapeutics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
- 12/13/2024 – Sangamo Therapeutics was upgraded by analysts at Truist Financial Co. from a “hold” rating to a “buy” rating. They now have a $7.00 price target on the stock.
- 12/10/2024 – Sangamo Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
- 12/6/2024 – Sangamo Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
- 11/28/2024 – Sangamo Therapeutics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
- 11/14/2024 – Sangamo Therapeutics had its price target raised by analysts at Barclays PLC from $3.00 to $9.00. They now have an “overweight” rating on the stock.
- 11/14/2024 – Sangamo Therapeutics was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
- 11/14/2024 – Sangamo Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
- 11/5/2024 – Sangamo Therapeutics had its price target raised by analysts at HC Wainwright from $5.00 to $10.00. They now have a “buy” rating on the stock.
- 10/22/2024 – Sangamo Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Sangamo Therapeutics Stock Performance
Shares of NASDAQ:SGMO traded up $0.17 during trading on Tuesday, reaching $2.82. 7,613,894 shares of the stock traded hands, compared to its average volume of 6,840,359. The stock has a market cap of $588.38 million, a P/E ratio of -3.76 and a beta of 1.15. The stock has a 50-day moving average of $1.88 and a two-hundred day moving average of $1.10. Sangamo Therapeutics, Inc. has a 52-week low of $0.30 and a 52-week high of $3.18.
Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. The firm had revenue of $49.41 million for the quarter, compared to the consensus estimate of $26.55 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. During the same period last year, the business posted ($0.34) EPS. Sell-side analysts expect that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current year.
Hedge Funds Weigh In On Sangamo Therapeutics
Large investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new position in shares of Sangamo Therapeutics during the third quarter valued at approximately $150,000. Geode Capital Management LLC lifted its holdings in shares of Sangamo Therapeutics by 14.6% during the third quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock worth $1,853,000 after purchasing an additional 272,123 shares during the period. XTX Topco Ltd lifted its position in Sangamo Therapeutics by 167.8% during the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 64,981 shares during the period. State Street Corp boosted its stake in shares of Sangamo Therapeutics by 28.0% in the third quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company’s stock worth $576,000 after buying an additional 145,400 shares during the last quarter. Finally, FMR LLC grew its holdings in Sangamo Therapeutics by 16.5% during the third quarter. FMR LLC now owns 544,003 shares of the biopharmaceutical company’s stock worth $471,000 after acquiring an additional 77,032 shares during the period. Institutional investors own 56.93% of the company’s stock.
Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.
Featured Stories
Receive News & Ratings for Sangamo Therapeutics Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sangamo Therapeutics Inc and related companies with MarketBeat.com’s FREE daily email newsletter.